Get the Daily Brief
Latest Biotech News
MD Anderson unveils $2.5B campaign: fundraising to transform cancer care
The University of Texas MD Anderson Cancer Center launched a $2.5 billion philanthropic campaign, 'Only Possible Here — The Campaign to End Cancer,' aimed at accelerating cancer research,...
Multi‑omics expose pig‑to‑human kidney immune barriers: rejection reversible
Researchers reported multi‑omics and physiologic analyses from a pig‑to‑human kidney xenotransplant in a brain‑dead recipient, mapping immune responses over a 61‑day period and identifying...
EMA advisers back five products: Telethon gene therapy for Wiskott‑Aldrich among them
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five new products, including a gene therapy developed by Fondazione Telethon for Wiskott‑Aldrich...
Merck stakes $9.2B on Cidara’s long-acting flu candidate
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD-388, a late-stage, long-acting antiviral designed to prevent influenza. The deal gives Merck a phase‑3 program that showed...
FDA narrows Elevidys label: boxed warning, ambulatory‑only restriction
The U.S. Food and Drug Administration revised the label for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys, adding a boxed safety warning and restricting use to ambulatory patients...
Lundbeck’s unsolicited bid ignites Avadel fight – Alkermes under pressure
Lundbeck submitted an unsolicited, higher offer for Avadel Pharmaceuticals, topping Alkermes’ earlier $2.1 billion agreement and setting off a bidding standoff for the Dublin‑based sleep‑disorder...
FDA clears Komzifti – new menin inhibitor approved for NPM1‑mutant AML
The FDA approved Kura Oncology and Kyowa Kirin’s ziftomenib (Komzifti) to treat relapsed or refractory acute myeloid leukemia with NPM1 mutations, based on phase II Komet‑001 data showing...
Pfizer closes up to $10B Metsera buy – fast‑acting obesity play locked in
Pfizer completed its acquisition of Metsera in a deal worth up to $10 billion, securing a fast‑acting amylin analog and a long‑acting GLP‑1 asset in a crowded obesity market. The close ends a...
Multi‑omics in pig‑to‑human kidney grafts maps rejection — and reversal
Researchers performed comprehensive multi‑omic and physiological profiling on a genetically engineered pig kidney transplanted into a brain‑dead human recipient and identified antibody‑ and...
Terasaki, Caltech win CIRM grant — Japan panel nudges embryo‑from‑stem‑cells path
The Terasaki Institute and Caltech secured a $2.8 million CIRM Discovery grant to study early human embryo formation using stem‑cell models, signaling renewed institutional investment in...
AI tools push drug‑target prediction and rapid resistance detection
Researchers released two AI‑driven advances: DeepTarget, a computational platform that predicts anti‑cancer mechanisms of small molecules and challenges single‑target drug paradigms; and...
CHMP recommends new medicines: Sanofi diabetes, Lilly SERD and five more
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued recommendations that include a Sanofi drug for type‑1 diabetes, Eli Lilly’s oral selective estrogen...
AMP issues draft guidelines for reporting cancer sequencing variants
The Association for Molecular Pathology’s AMP Group released draft guidelines for interpreting and reporting cancer sequencing variants, covering biomarkers for therapy response/resistance, liquid...
Merck stakes $9.2B on Cidara – buys late‑stage flu antiviral
Merck agreed to acquire San Diego biotech Cidara Therapeutics for $9.2 billion to secure CD‑388, a long‑acting antiviral aimed at season‑long prevention of influenza A and B. The deal prices...
Pfizer seals up to $10B Metsera deal – picks up fast‑acting obesity asset
Pfizer completed its acquisition of Metsera in a transaction worth up to $10 billion, gaining the obesity biotech’s fast‑acting amylin/GLP assets and a long‑acting GLP‑1. The deal ends a...
Lundbeck jumps into Avadel fight – forces Alkermes into tougher spot
Danish drugmaker Lundbeck filed an unsolicited offer for Avadel Pharmaceuticals that topped an earlier agreement between Avadel and Alkermes, igniting a cross‑border bidding tussle over a marketed...
FDA clears Kura’s menin inhibitor – new option for NPM1‑mutant AML
The U.S. Food and Drug Administration approved Kura Oncology and Kyowa Kirin’s oral menin inhibitor ziftomenib (Komzifti) for relapsed or refractory acute myeloid leukemia (AML) with NPM1...
Pig kidney xenotransplant mapped: multi‑omics traces rejection and rescue
Researchers performed a pig‑to‑human kidney xenotransplant into a brain‑dead recipient and ran comprehensive multi‑omics and physiological monitoring over 61 days, revealing the immune dynamics...
FDA tightens Sarepta’s Elevidys label – boxed warning and use limits
The FDA revised the prescribing information for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys to include a boxed safety warning and to limit use to ambulatory patients,...
EMA advisers back five products – charity‑led gene therapy clears EU hurdle
The European Medicines Agency’s CHMP recommended five new medicinal products, including Fondazione Telethon’s ex‑vivo gene therapy Waskyra (etuvetidigene autotemcel) for Wiskott‑Aldrich syndrome....